Two Milestone Studies in Liver Cancer Immunotherapy.
NEJM Evid
; 1(8): EVIDe2200140, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-38319792
ABSTRACT
Immunotherapy has changed the playing field for multiple cancers, and prime time for unresectable liver cancers may be here now. This issue of NEJM Evidence includes two trials describing novel immunotherapy options for patients with biliary tract cancer and hepatocellular carcinoma. Oh et al.1 describe the results of the TOPAZ-1 trial, which resulted in improved overall survival for patients with biliary tract cancer in the frontline setting - the first real advance in more than a decade.2 Abou-Alfa et al.3 present results from the HIMALAYA study.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
NEJM Evid
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Moldávia